American Society of Clinical Oncology (ASCO) Annual Meeting

Baylor University Medical Center at Dallas (Baylor Dallas), part of Baylor Scott & White Health, will present posters and oral presentations at the prestigious May 30th to June 2nd 2025 ASCO annual meeting in Chicago, IL. Key presentations include: Gastroesophageal cancer Ronan Kelly, MD, MBA, chief of oncology at Baylor Scott & White North Texas and director of the Baylor Scott & White Charles A. Sammons Cancer Center will present the first overall survival results from the landmark CheckMate 577 trial of adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer at the oral abstract session for GI malignancies on May 31st (abstract 4000 ). This significant oral presentation was selected as one of best abstracts of the ASCO Meeting by the Best of ASCO committee. Dr. Kelly will also present new findings from a multicenter phase I/II study of the CDK 4/6 inhibitor abemaciclib and the VEGFR2 antagonist ramucirumab in metastatic gastroesophageal adenocarcinoma (abstract 4063 ). Breast Cancer Joyce O’Shaughnessy, MD, the Celebrating Women Chair in Breast Cancer Research at Baylor Dallas, will present new safety results from the EMBER-3 trial of the selective estrogen receptor degrader (SERD) imlunestrant with or without abemaciclib in advanced breast cancer (abstract 1060 ) and the HERTHENA-Breast03 trial (abstract TPS629 ) of neoadjuvant patritumab deruxtecan plus pembrolizumab for early-stage breast cancers. Texas Cancer Interception Institute (TCII) Innovations Four presentations involving Dr. Kelly will highlight the TCII’s pioneering work in early cancer detection , using advanced technologies such as machine learning for evaluation of CT scans (abstract 1559 ), multiplex blood biomarker screening in the Texas Multi-Cancer Early Detection (Texas MCED) program (abstract TPS11189 ), cell-free DNA (cfDNA) for treatment monitoring (abstract 2550 ), and plasma proteomics (abstract 8579 ).  “The TCII is developing into a powerful